A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
- Conditions
- Squamous Cell Carcinoma of the OropharynxHPV16 Positive
- Interventions
- Registration Number
- NCT03669718
- Lead Sponsor
- ISA Pharmaceuticals
- Brief Summary
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
- Detailed Description
This study will assess the ability of ISA101b to improve Overall Response Rate in subjects with HPV16 positive OPC, when combined with cemiplimab, an investigational anti-PD-1 antibody being developed by Regeneron Pharmaceuticals. ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16. Trials in HPV16 driven malignancies indicate it has activity in HPV16 driven malignancies including oropharyngeal and cervical cancers. Cemiplimab, also known as REGN2810, is in late stage trials and appears to have similar activity to approved anti PD-1 antibodies in a number of malignancies .
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 194
- Males and females, ≥ 18 years of age.
- Sign and date an Institutional Review Board/Independent Ethics Committee (IRB)/(IEC)-approved written informed consent form (ICF) in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
- Be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
- Diagnosed with histologically confirmed recurrent or metastatic HPV16 positive OPC, whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) and who are candidates for first line therapy with an PD-1 blocking antibody, AND subjects with recurrent or metastatic HPV16 positive OPC with disease progression on or after platinum containing chemotherapy.
- HPV-16 genotyping will be determined by the specified central reference laboratory.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria.
- Prior curative radiation therapy must have been completed at least 4 weeks prior to study drug administration. Prior focal palliative radiotherapy must have been completed at least 2 weeks before study drug administration.
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study drug.
Exclusion criteria:
- Subjects with previously untreated metastatic or unresectable, recurrent HPV16 positive OPC whose tumors do not express PD-L1 (CPS<1) and who are therefore not candidates for monotherapy with an anti-PD-1 antibody.
- Subjects with known brain metastases or leptomeningeal metastases.
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
- History of other malignancy ≤ 3 years prior to entry into this trial with the exception of basal cell or squamous cell skin carcinoma which were treated with local resection only, or carcinoma in situ of the cervix, prostate or breast, or low grade non-muscle invasive superficial bladder cancer (TaLG)/carcinoma in situ of the bladder.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Subjects with a condition requiring immunosuppressive doses of systemic medication such as steroids or absorbed topical steroids (doses ≥ 10 mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Prior treatment with an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab, cemiplimab), as well as an antibody targeting anti-PL-L1 anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co stimulation or immune checkpoint pathways.
- Prior treatment with more than one chemotherapy regimen for the management of metastatic OPC.
- Prior treatment with therapeutic anti-HPV vaccines including ISA101 or ISA101b. Subjects may have received a preventive HPV vaccine.
- All toxicities attributed to systemic prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE) or baseline before administration of study drug. Subjects with toxicities attributed to systemic prior anticancer therapy that are not expected to resolve and result in long lasting sequelae, such as neuropathy after platinum based therapy, are permitted to enroll.
- History of allergy to ISA101/ISA101b study drug components, e.g., ISA101/101b, Montanide, or Macrogolglycerol Ricinoleate, also known as cremophore.
- History of allergy to cemiplimab and its excipients.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Active ISA101b and cemiplimab. Cemiplimab ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months Placebo and cemiplimab Placebo Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months Active ISA101b and cemiplimab. ISA101b ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months Placebo and cemiplimab Cemiplimab Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
- Primary Outcome Measures
Name Time Method Overall Response Rate 25months Measured using RECIST 1.1
Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0 "Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0". 25 months
- Secondary Outcome Measures
Name Time Method Duration of response (DOR) by independent review in subjects randomized to receive ISA101b plus cemiplimab compared to placebo plus cemiplimab. 25months
Trial Locations
- Locations (44)
Nemocnice na Bulovce
🇨🇿Prague, Czechia
Consultorio de Oncología Médica
🇲🇽Oaxaca, Mexico
ASST Spedali Civili Brescia, Department of Medical Oncology
🇮🇹Brescia, Italy
Istituto Nazionale dei Tumori
🇮🇹Milan, Italy
University Hospital Antwerp
🇧🇪Antwerp, Belgium
Hetenyi Geza Korhaz-Rendelointezet
🇭🇺Szolnok, Hungary
Maria Sklodowska-Curie National Institute of Oncology
🇵🇱Gliwice, Poland
Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz
🇭🇺Nyiregyhaza, Hungary
ICAHN School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Swietokrzyskie Oncology Center Kielce
🇵🇱Kielce, Poland
Radboud University Medical Center
🇳🇱Nijmegen, Netherlands
Centre Léon Bérard
🇫🇷Lyon, France
CHU La Timone
🇫🇷Marseille, France
City of Hope
🇺🇸Duarte, California, United States
Moores Cancer Center at the UC San Diego Health
🇺🇸San Diego, California, United States
University of California San Francisco
🇺🇸San Francisco, California, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Robert H. Lurie Comprehensive Cancer Center
🇺🇸Chicago, Illinois, United States
UPMC Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
M. D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
DFSATR/Oncologia D'Or
🇧🇷Brasília, Brazil
University of Cincinnati Cancer Institute
🇺🇸Cincinnati, Ohio, United States
Instituto do Cancer do Estado de Sao Paulo
🇧🇷Sao Paulo, Brazil
University Hospital Olomouc
🇨🇿Olomouc, Czechia
Hopitaux Universitaires Pitié Salpêtrière Charles Foix
🇫🇷Paris, France
Gustave Roussy
🇫🇷Paris, France
Antoine Lacassagne Center
🇫🇷Nice, France
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
University of Pecs Department of Oncotherapy
🇭🇺Pecs, Hungary
National Cancer Institute - IRCCS "Fondazione G. Pascale"
🇮🇹Naples, Italy
Azienda Ospedaliera San Paolo Polo Universitario
🇮🇹Milan, Italy
National Cancer Institute Regina Elena, IRCCS
🇮🇹Rome, Italy
Antoni van Leeuwenhoek Ziekenhuis
🇳🇱Amsterdam, Netherlands
Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic of Barcelona
🇪🇸Barcelona, Spain
Hospital Duran i Reynals - Institut Catala dOncologia ICO
🇪🇸Barcelona, Spain
Hospital Universitario Marqués de Valdecilla Santander
🇪🇸Santander, Spain
Aberdeen Royal Infirmary
🇬🇧Aberdeen, United Kingdom
The Royal Marsden NHS Foundation
🇬🇧Chelsea, United Kingdom
Beacon Centre Musgrove Park Hospital
🇬🇧Taunton, United Kingdom
The Royal Marsden NHS Foundation Trust
🇬🇧Sutton, United Kingdom
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Guy's Hospital
🇬🇧London, United Kingdom
University Medical Center Utrecht
🇳🇱Utrecht, Netherlands